CV Sciences, Inc. Cash Flow Statement
CVSI|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$407,000
FY2025
Free Cash Flow
-$516,000
FY2025
Capital Expenditures
$109,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
CV Sciences, Inc. used $407,000 in operating cash flow and negative free cash flow of $516,000 in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -8.81 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -65.3% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$958.0K | -$2.4M | $3.1M | -$8.2M | -$15.6M | -$22.3M | -$16.6M | $10.0M | -$4.9M | -$14.1M | -$12.2M | -$1.3M | -$2.3M |
| Depreciation & Amortization | $192.0K | $334.0K | $235.0K | $992.0K | $1.2M | $872.0K | $716.0K | $519.0K | $183.0K | $1.1M | $1.0M | $933.6K | $767.3K |
| Operating Cash Flow | -$407.0K | -$861.0K | $2.3M | -$1.9M | -$7.5M | -$7.3M | -$2.2M | $12.6M | $3.6M | -$2.1M | -$4.2M | -$6.7M | -$4.9M |
| Capital Expenditures | $109.0K | $18.0K | $0 | $0 | $35.0K | $1.1M | $1.1M | $893.0K | $454.0K | $17.2K | $113.5K | $449.2K | $226.6K |
| Free Cash Flow | -$516.0K | -$879.0K | $2.3M | -$1.9M | -$7.5M | -$8.4M | -$3.4M | $11.7M | $3.2M | -$2.1M | -$4.3M | -$7.2M | -$5.1M |
| FCF Margin | -3.7% | -5.6% | 14.1% | -11.6% | -37.5% | -34.2% | -6.3% | 24.2% | 15.3% | -18.7% | -37.5% | -70.3% | -237.0% |